One of Cathie Wood's Ark Invest funds sold over 1.5 million shares of Workhorse on May 11.
A couple of Cathie Wood's ARK Invest funds sold over 150,000 shares of Alibaba on August 16.
China is facing an outbreak of the coronavirus, which may have spread to a few other countries in Asia. As a result, experimental vaccine stocks are skyrocketing.
Sarepta Therapeutics cleared another hurdle related to its Duchenne muscular dystrophy treatment, and the stock practically doubled on Monday.
Sarepta Therapeutics Inc. (NASDAQ: SRPT) is a company which many biohealth and biotech investors have likely never heard of. At least before today. How many shares rise more than 150% when there is...
The sad news that Ebola patient Thomas Eric Duncan has died in a Dallas hospital now raises fears that Ebola drugs might not be a cure-all for patients.
These are the top analyst upgrades, downgrades and initiations seen from Wall Street research firms on Tuesday, October 28, 2014.
Barclays recently issued a few calls across multiple industries implying serious upside for each stock, but one in particular with over 30% upside.
One of Cathie Wood's Ark Invest funds sold over 500,000 shares of Huya on May 14.
Amicus Therapeutics is another biotech player seeing a nice boost from the World Muscle Society Conference in France.
Sarepta Therapeutics shares took a big hit on Monday morning as disappointing news started its week out on the wrong foot.
Wednesday's leading analyst upgrades, downgrades and initiations from top research calls from around Wall Street include Exxon, Lowe's, Paycom Software, Under Armour, Wal-Mart and Verizon...
One of Cathie Wood's Ark Invest funds sold over 831,000 shares of Pure Storage on May 13.
Catabasis Pharmaceuticals shares continued their incredible climb after the announcement of positive efficacy results from its MoveDMD trial in a late-breaking session at the World Muscle Society...
Credit Suisse's $36 price target on Sarepta Therapeutics effectively calls for close to 75% upside.